Evidence map›Paper›PMID 33573869›Full record

Observational studyAnais brasileiros de dermatologia

Socioeconomic impact of high-cost drugs in Brazilian dermatology. Legal and financial aspects, and impact on clinical practice.

Renan Tironi Giglio de Oliveira, Giovana Larissa Prado Leite Agostinho, Rubens Granja, Luiza Keiko M Oyafuso, Paulo Ricardo Criado

Abstract readObservational Study
In one paragraph

Observational study in Anais brasileiros de dermatologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Renan Tironi Giglio de OliveiraDermatology Residence Program, Centro Universitário FMABC, Santo André, SP, Brazil. Electronic address: renantironi@hotmail.com.
Giovana Larissa Prado Leite AgostinhoDermatology Course, Centro Universitário FMABC, Santo André, SP, Brazil.
Rubens GranjaCivil Law Discipline, School of Law, Universidade de São Paulo, São Paulo, SP, Brazil.
Luiza Keiko M OyafusoDermatology Course, Centro Universitário FMABC, Santo André, SP, Brazil.
Paulo Ricardo CriadoDermatology Course, Centro Universitário FMABC, Santo André, SP, Brazil.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The technological advancement of the pharmaceutical industry, resulting from the techniques of molecular biology and expansion of the knowledge of immunopathogenesis, has modified the therapeutic arsenal used in dermatology. Scientific research and regulatory standards cause drug costs to rise, thus making their use impossible in most public policies. In order to make high-cost drugs viable in the public health network, the Specialized Pharmaceutical Assistance Component was created. However, despite the frequent incorporation of medications, the constant requirement of drugs through lawsuits leads to exorbitant costs to the state budget. The present work analyzed through a descriptive observational study, the current situation of the Specialized Component and the involvement of medicines used in dermatology, through legal reviews, financial analyses, and medical articles, aiming at future incorporations for the specialty. When assessing the legal demands for dermatological drugs in the state of São Paulo, the specialty still has a low participation and psoriasis is the main disease involved in requiring drugs through the judicial system in the state. New methods of access to raw materials must be created to reduce legal issues. Cost-effectiveness and public planning studies are mandatory for incorporating new dermatological therapies.

Indexed as

DermatologyPharmaceutical PreparationsBrazilDrug CostsHumansSocioeconomic FactorsPharmaceutical PreparationsDermatologyLegal health issuesSpecialized pharmaceuticals

Identifiers

PMID33573869
PMCPMC8007493

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.